Study Launched to Assess Methadone Pharmacokinetics
Marianthi Markatou, professor and associate chair of research and healthcare informatics, University at buffalo, SUNY.
While the opioid epidemic is ever-present across the nation, UB plans to research an opioid addiction treatment associated with the function of liver fibrosis. The new research award is funded from the University of Rochester and National Institutes of Health.
Marianthi Markatou, professor and associate chair of research and healthcare informatics in the Department of Biostatistics, School of Public Health and Health Professions, is a key player in the project titled, "A Study of Methadone Pharmacokinetics in Patients with and without Liver Fibrosis, Hepatitis C Virus (HCV) infection, and HCV/HIV Co-Infection."
Also known as MeDiCALF (Methadone Disposition Changes Associated with Liver Fibrosis), the main aim of the study is to assess methadone pharmacokinetics as a function of liver fibrosis. Methadone is a synthetic opioid used in the treatment of opioid addiction.
The use of methadone is considered an important strategy in the prevention of acquisition of HIV and viral hepatitis in individuals with high-risk behaviors. Methadone pharmacokinetics are characterized by substantial inter-individual variability, the sources of which remain largely unknown.
“What we hypothesize is that liver impairment results in impaired methadone metabolism,” explains Markatou. “This can lead to the possibility of methadone toxicity that can potentially lead to death.”
Markatou also notes that statistical modeling offers a useful avenue for the study of pharmacokinetic properties of methadone.
“Mixed effects models, in this particular instance, can help us create new methodological research, research that will ultimately be used in this study.”
In addition to UB’s Markatou, this study is a collaboration between the University of Rochester, Washington University in Saint Louis and START Treatment and Recovery Center in New York City.
This article has been republished from materials provided by University at Buffalo. Note: material may have been edited for length and content. For further information, please contact the cited source.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE